Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?

Core Viewpoint - Gilead Sciences, Inc. is expected to report its fourth-quarter and full-year 2024 results on February 11, with sales and earnings estimates at $7.06 billion and $1.66 per share respectively [1] Earnings Performance - Gilead has beaten earnings estimates in three of the last four quarters, with an average surprise of 15.46% [2] Earnings Prediction - The model predicts an earnings beat for Gilead, supported by a positive Earnings ESP of +1.70% and a Zacks Rank of 3 (Hold) [3] Factors Influencing Q4 Results - Gilead's HIV franchise, particularly Biktarvy and Descovy, is expected to drive sales, with Biktarvy sales estimated at $3.46 billion and Descovy at $574 million [4][5] - The Liver Disease portfolio is likely to benefit from increased demand for viral hepatitis medicines and the launch of Livdelzi for primary biliary cholangitis [5][6] Sales Estimates - Sales for Cell Therapy products are estimated at $480 million, with a potential decrease due to competitive pressures [7] - Trodelvy sales are estimated at $282 million, with potential impacts from market conditions [8][9] Recent Developments - Trodelvy received Breakthrough Therapy Designation from the FDA for extensive-stage small cell lung cancer [10] - The European Medicines Agency recommended seladelpar for PBC treatment, with a final decision expected in Q1 2025 [11] Stock Performance - Gilead's shares have increased by 31.8% over the past year, contrasting with a 6.3% decline in the industry [14]